The inspection was concluded on 14 February 2020.
Granules India in an exchange filing on Saturday said that US Food & Drug Administration (US FDA) has completed inspection of the facility located in Gagillapur, Hyderabad on 14 February 2020. The inspection was concluded with two observations.The company assured that it will respond to these observations within stipulated time.
Commenting on the US FDA Audit, Krishna Prasad, Chairman and Managing director, Granules India said, We successfully completed an FDA audit with two observations, which are being addressed and will respond to the FDA within the stipulated time. These observations will not affect the business continuity.
Shares of Granules India were trading 1.05% higher at Rs 177.5 on BSE.
Granules India is a growing pharmaceutical manufacturing company. The company produces finished dosages (FDs), pharmaceutical formulation intermediates (PFIs) and active pharmaceutical ingredients (APIs).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app